A phase II trial of carboplatin in patients with advanced APUD tumors

Background. Chemotherapy remains inadequate for patients with carcinoid tumors, islet cell tumors, and medullary carcinomas of the thyroid. Carboplatin has shown activity in oat cell carcinoma of the lung, another tumor of neuroectodermal origin.

[1]  S. Lipsitz,et al.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. , 1992, The New England journal of medicine.

[2]  L. Kvols,et al.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.

[3]  M. Eisenberger,et al.  A phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus , 1991, Cancer.

[4]  K. Öberg,et al.  Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. , 1989, European journal of cancer & clinical oncology.

[5]  L. Kvols,et al.  Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Kemeny,et al.  A Phase II Trial of Streptozotocin and Adriamycin in Advanced APUD Tumors , 1988, American journal of clinical oncology.

[7]  E. Wilander,et al.  TREATMENT OF MALIGNANT ENDOCRINE PANCREATIC TUMOURS WITH HUMAN LEUCOCYTE INTERFERON , 1986, The Lancet.

[8]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[9]  S. Carter,et al.  Carboplatin: the clinical spectrum to date. , 1985, Cancer treatment reviews.

[10]  P. Lavin,et al.  Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. V. van Putten,et al.  Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. , 1984, European journal of cancer & clinical oncology.

[12]  C. Moertel.  Treatment of the carcinoid tumor and the malignant carcinoid syndrome. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Hanley,et al.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. , 1980, The New England journal of medicine.

[14]  R. Golbey,et al.  High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis , 1977, Cancer.

[15]  V. Devita,et al.  Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998) , 1974, Cancer.

[16]  S. Carter,et al.  Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. , 1973, Annals of internal medicine.

[17]  Moertel Cg,et al.  Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. , 1979 .